EndpointsAug 271 min read

Moderna to raise $2 billion via convertible senior notes to fund oncology expansion and reduce debt

Aug 27, 2026read at Endpoints ↗DealNeutral

Moderna announced it will issue $2 billion of convertible senior notes. The company says the financing will give it flexibility to invest in its growing oncology portfolio and to repay existing debt.

The convertible notes are intended to provide capital while allowing investors the option to convert the debt into equity under predefined terms.

The briefing also mentioned that AstraZeneca‑Amgen and Biokin reported Phase 3 trial successes, and it referenced additional news about Takeda China and ProFound, though no further details were provided.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins”

read at Endpoints ↗

76 words · retrieved Aug 27

sharex / twitter linkedin

Moderna to raise $2 billion via convertible senior notes to fund oncology expansion and reduce debt

comments(0)

Moderna to raise $2 billion via convertible senior notes to fund oncology expansion and reduce debt

comments(0)

Moderna to raise $2 billion via convertible senior notes to fund oncology expansion and reduce debt

comments(0)

Moderna to raise $2 billion via convertible senior notes to fund oncology expansion and reduce debt

comments(0)

Moderna to raise $2 billion via convertible senior notes to fund oncology expansion and reduce debt

Moderna to raise $2 billion via convertible senior notes to fund oncology expansion and reduce debt